A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

PHASE2TerminatedINTERVENTIONAL

Enrollment

143

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Seasonal Allergic Conjunctivitis to Ragweed

Interventions

DRUG

Olopatadine

low dose

DRUG

Olopatadine

high dose

Trial Locations (1)

Cetero Research, Toronto